Navigation Links
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection

SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. , a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis and cancer, announced today that it has nominated ANA598 as a candidate for clinical development as an orally-administered direct antiviral for the treatment of chronic hepatitis C virus (HCV) infection.

"We have identified a small-molecule, non-nucleoside inhibitor of the NS5b polymerase that, based on pre-clinical studies conducted to date, has shown favorable antiviral, metabolic, pharmacokinetic, and preliminary toxicologic properties, and is the culmination of several years of work in our HCV direct antiviral discovery program," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Anadys. "We are now conducting additional pre-clinical studies in anticipation of submitting an Investigational New Drug application (IND) in the second quarter of 2008."

Preclinical Study Results

In a series of in vitro pre-clinical studies ANA598 demonstrated excellent potency against HCV genotype 1 NS5b polymerase and potent activity in HCV replicon assays. The compound also displayed very good in vitro metabolic stability and did not significantly inhibit human CYP enzymes, suggesting a low potential for drug-drug interactions. Extending these in vitro findings, in vivo preclinical studies of ANA598 demonstrated high oral bioavailability and good tolerability. Also, drug levels were sustained in the plasma and in the liver, the principal site of HCV replication.

"The current standard of care is inadequate for many chronic HCV patients, including about half of those with genotype 1 disease," said Steve Worland, Ph.D., president, Pharmaceuticals. "We believe ANA598 possesses favorable characteristics that may enable it to play an important role in future HCV thera
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:7/6/2015)... Research and Markets( http://www.researchandmarkets.com/research/58tdl6/pharmaceutical ... Grade Sodium Chloride Market by Applications, by Region - ... their offering. The pharmaceutical grade sodium chloride ... between 2014 and 2019 in terms of volume, and ... 2019. The report on Pharmaceutical grade sodium ...
(Date:7/6/2015)... HAYWARD, Calif. , July 6, 2015  Impax ... Larry Hsu , Ph.D. has resigned from the ... business activities. Dr. Hsu was a co-founder of Impax ... Chief Executive Officer from October 2006 until April 2014. ... Fred Wilkinson , Impax,s President and Chief Executive ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 2Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 3Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 4Impax Announces Resignation of Larry Hsu, Ph.D. from Board of Directors 5CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... The U.S. Food and Drug Administration today approved ... with acute lymphoblastic leukemia (ALL), who have developed an ... and pegaspargase chemotherapy drugs used to treat ALL. ... Acute lymphoblastic leukemia is a type of cancer in ...
... Technologies, Inc. (the "Company") (Nasdaq: CMED ), a leading China-based ... second fiscal quarter ended September 30, 2011 ("2Q FY2011") today. ... M onths Ended September 30, ... Months   EndedSeptember   30, ...
Cached Medicine Technology:FDA Approves Erwinaze to Treat a Form of Leukemia 2FDA Approves Erwinaze to Treat a Form of Leukemia 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14China Medical Technologies Reports Second Fiscal Quarter Financial Results 15China Medical Technologies Reports Second Fiscal Quarter Financial Results 16China Medical Technologies Reports Second Fiscal Quarter Financial Results 17China Medical Technologies Reports Second Fiscal Quarter Financial Results 18China Medical Technologies Reports Second Fiscal Quarter Financial Results 19China Medical Technologies Reports Second Fiscal Quarter Financial Results 20China Medical Technologies Reports Second Fiscal Quarter Financial Results 21China Medical Technologies Reports Second Fiscal Quarter Financial Results 22China Medical Technologies Reports Second Fiscal Quarter Financial Results 23China Medical Technologies Reports Second Fiscal Quarter Financial Results 24
(Date:7/6/2015)... ... ... Olive Fertility Centre is proud to announce that Olive medical director Dr. ... the department of Family Practice. , “This award is a real honour,” says Dr ... is changing so rapidly and we are also developing new models of patient-centred care ...
(Date:7/6/2015)... ... July 06, 2015 , ... Seedstock today announced Pierre Sleiman, founder and ... 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation and the Small Farmer” – to ... the University of California-San Diego, will explore solutions and methodologies that small farmers and ...
(Date:7/6/2015)... ... 2015 , ... With a new community program in the Livonia, Canton and ... announced a new charity campaign to raise funds in support of the health and ... Save Our Youth is a coalition created especially to educate and empower teens, bringing ...
(Date:7/6/2015)... ... July 06, 2015 , ... Orthopaedic & Spine ... 100th case using SpineFrontier’s® PedFuse® REmind® Screws. The operation took place on Tuesday, ... The procedure was an L5-S1 posterior lumbar interbody fusion on a 69 year ...
(Date:7/5/2015)... ... 06, 2015 , ... City Sports, the Boston-based specialty sporting goods retailer, has ... for first-time triathletes this summer with ethos, the owner and operator of the Boston ... at 6:00 p.m. at the North End Greenway. The event will help new triathletes ...
Breaking Medicine News(10 mins):Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 2Health News:Bowker Insurance Group and Nonprofit Livonia Save Our Youth Initiate New Charity Campaign in Livonia, MI to Provide for The Health and Safety of The Communities’ Youth 3Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 2Health News:100th Outpatient Less Exposure Surgery Procedure Completed by Industry Leading Surgeon Dr. Jeffrey Carlson 3Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... as the Nintendo Wii Remote, could be used in the ... caused by a stroke, that affects around 250,000 people in ... a team at City University London, in collaboration with the ... Research Council (EPSRC). The aim is to develop ...
... State College of Medicine found significant racial disparities in the ... of hospital admission for cardiovascular disease (CVD) events and CVD-related ... with CVD and to have an in-hospital death due to ... of Arthritis & Rheumatism , a journal published by ...
... Researchers at the University of Michigan and Arbor Research ... geographic variation as a key factor accounting for disparities ... groups. Full details appear in the September issue of ... on behalf of the American Association for the Study ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Aug. 18 ... median survival from 6.4 months to 10 months, which, although ... normally intractable disease, a new study found. And a ... as long as six years, according to research published in ...
... By Dennis Thompson HealthDay Reporter , THURSDAY, Aug. ... the WorkSource Center office in Salem, Ore. The people waiting ... and tense. One person who jumped the line received a lecture ... "You have to be careful," the woman said. "There are a ...
... in the treatment of patients with advanced lung cancer ... it also extended their lives. In the August ... General Hospital (MGH) investigators report that patients with metastatic ... along with standard treatment lived more than two months ...
Cached Medicine News:Health News:Wii-like technologies may help stroke survivors improve communication skills 2Health News:Black women with SLE develop cardiovascular disease at early age 2Health News:Black women with SLE develop cardiovascular disease at early age 3Health News:Hispanics and Asians less likely to receive liver transplants 2Health News:Hispanics and Asians less likely to receive liver transplants 3Health News:Trial Therapy Improves Melanoma Survival 2Health News:Trial Therapy Improves Melanoma Survival 3Health News:Jobless and Stressed but Holding Out Hope 2Health News:Lung cancer patients receiving palliative care had improved quality of life, extended survival 2Health News:Lung cancer patients receiving palliative care had improved quality of life, extended survival 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: